Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Executive Summary
Arena reported statistically and "clinically" significant results from its Phase II study for ralinepag in pulmonary arterial hypertension (PAH), driving its share price up by more than 40%, but details expected later this year or in 2018 are needed to shed more light on the data.
You may also be interested in...
Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.
On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study
Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.
Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.